Magnetic resonance imaging (MRI) is recognized as the most accurate modality for assessing brain tumors and is adept at evaluating lesion morphology and enhancement characteristics [1]. In particular, contrast-enhanced MRI provides essential information for monitoring disease progression and treatment efficacy, as well as for determining therapeutic strategies, such as surgical resection or radiotherapy, as these decisions rely heavily on the number, size, and location of intracranial lesions [2…